Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs
about
Role of biologics in severe eosinophilic asthma - focus on reslizumabPersonalized Medicine in AllergyTherapeutic interventions in severe asthmaAspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the futureMepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.Novel Modulators of Asthma and Allergy: Exosomes and MicroRNAs.Emerging pharmaceutical therapies for COPD.Mechanisms by which obesity impacts upon asthma.The safety of monoclonal antibodies in asthma.The path to personalized medicine in asthma.Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations.Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?Prospects for new and emerging therapeutics in severe asthma: the role of biologics.Role of Type 2 Innate Lymphoid Cells in Allergic Diseases.Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) as a differential diagnosis of hypereosinophilic syndromes.IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils.Human group 2 innate lymphoid cells do not express the IL-5 receptor.Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer.Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma.Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.Eosinophils: The unsung heroes in cancer?Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in asthmatic children.The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC.Mast cells as sources of cytokines, chemokines, and growth factors.The role of interleukin 5 in asthma.Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults.Samter's Triad: State of the Art.Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.Interactions between dendritic cells and T lymphocytes in pathogenesis of nasal polyps.
P2860
Q26738503-231EE55E-7A86-41D3-A124-BDCDD27F6A02Q28073074-87895C5D-43DC-4470-B587-B785AFD55319Q28079238-CE81CE97-DF75-4282-97BF-13C19928D302Q30238776-6DFF25A2-B2C7-40B0-BB24-1E7464E6AAF3Q34544937-B0D60472-5FD1-44BC-BD88-DA02C97B4920Q38635913-32561B9E-7051-45B8-A097-C8F8C0CD5745Q38645203-99FEEFB0-47CD-49C3-A7FB-48A2732DC2F3Q38817338-6A58FC54-F66A-418B-BF61-57F6F822EDB7Q38842153-379B1DB5-9708-48EC-8C7D-7D2CF23AFAFEQ38843261-20DD05AA-9616-48B8-9967-05237AB98FFCQ39189229-7BD1C971-934C-453E-A1F6-8E7D9FAAB953Q39201543-B7B56873-B6B4-4D9A-B2E5-BDAAF42262A4Q39278773-A9D8B8FD-64E0-4190-9E99-B9933423DA58Q40051865-C40C097D-4720-457C-8803-4BDD64D0BD21Q40064071-7736F588-CEF9-47B9-B84B-30A0785C2F21Q40146282-A8D2F2B4-2629-4CCE-86DD-6C9EA583CBB7Q40213557-AE963A65-91C3-465E-B768-5EED1B22B7B5Q41098587-A928D4FD-4CB9-4F05-AC05-F222B17A174EQ41605623-EF3E6400-E7D8-4ACA-A623-2BFED48D8787Q45676532-F4D739CC-14D3-4470-BDDF-10938FD0361EQ47225787-7E3E5393-7D59-487E-B77D-C84399DFA736Q47429419-5EED1245-55C1-4439-BD76-DDB49074244EQ47553695-61FC74DF-9A71-46EF-805F-0C5200E12710Q50068970-9AEF33C2-32E7-4A76-8A6C-77463207C536Q51483829-37AB4BA0-428E-4593-8845-F779F1893C91Q52571066-8B781E51-EFCF-42B1-AB74-EF5327B10368Q52657068-3BE17D6C-F9A1-4140-9656-B98EEC172491Q54940852-CC983F43-F61D-4BBD-BA68-B544635B0B8DQ55003087-7BDA325D-8A83-468B-A33D-6FC809C1FB8BQ55004171-E17176CA-6D20-4F06-BED0-6297E59A4FE8Q55248689-C7088CC3-51E3-4F87-A84C-A79CBDEF09C3
P2860
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Interleukin-5 pathway inhibiti ...... ders: evidence and unmet needs
@ast
Interleukin-5 pathway inhibiti ...... ders: evidence and unmet needs
@en
Interleukin-5 pathway inhibiti ...... ders: evidence and unmet needs
@nl
type
label
Interleukin-5 pathway inhibiti ...... ders: evidence and unmet needs
@ast
Interleukin-5 pathway inhibiti ...... ders: evidence and unmet needs
@en
Interleukin-5 pathway inhibiti ...... ders: evidence and unmet needs
@nl
prefLabel
Interleukin-5 pathway inhibiti ...... ders: evidence and unmet needs
@ast
Interleukin-5 pathway inhibiti ...... ders: evidence and unmet needs
@en
Interleukin-5 pathway inhibiti ...... ders: evidence and unmet needs
@nl
P2093
P2860
P921
P3181
P1476
Interleukin-5 pathway inhibiti ...... ders: evidence and unmet needs
@en
P2093
Enrico Heffler
Francesco Borriello
Gilda Varricchi
P2860
P304
P3181
P356
10.1097/ACI.0000000000000251
P407
P5008
P577
2016-04-01T00:00:00Z